会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 22. 发明申请
    • UNITARY MULTI-COMPONENT FILTER MEDIA
    • WO2002009845A3
    • 2002-02-07
    • PCT/US2001/023627
    • 2001-07-27
    • LYDALL, INC.
    • POSA, James, M.MCCARTHY, Michael, P.
    • B01D39/16
    • A high efficiency particulate air (HEPA) filter made from a layer of electrostatically-charged thermoplastic fiber scrim that is point-bonded to a layer of glass fiber batting to form a composite layer defining an area, wherein the point-bonding is distributed over substantially all of the area of the composite layer and the bond points constitute approximately 1 % to approximately 6 % of the total surface area of the welded filter material, and wherein the composite layer is substantially uncompressed. Also, a process for forming the filter by providing an ultrasonic rotary drum having a large number of projections from the surface of the drum, passing a layer of electrostatically-charged thermoplastic fiber scrim resting on top of a layer of glass fiber batting over said drum in such a manner that said projections do not substantially penetrate into the subassembly, and passing the subassembly resting on top of the projections under an ultrasonic horn emitting high frequency sound waves into the subassembly to form point-bonds in the vicinity of the projections.
    • 26. 发明申请
    • METHOD FOR TREATING INFLUENZA A VIRUS INFECTION
    • 用于治疗流感病毒感染的方法
    • WO2016109541A1
    • 2016-07-07
    • PCT/US2015/067870
    • 2015-12-29
    • ACADEMIA SINICALIANG, Chi-Ming
    • HSIEH, Shie-LiangCHANG, Yung-ChiHUANG, Ming-Ting
    • A61K38/00
    • A61K38/177C07K14/70578C07K2319/30
    • Disclosed herein is a method of treating influenza A virus (IAV) infection by a fusion protein. According to some embodiments of the present disclosure, the fusion protein comprises a HBD peptide and a IgG1 Fc region. According to other embodiments of the present disclosure, the fusion protein comprises a DcR3 protein and a IgG1 Fc region. The present fusion protein is found to possess inhibitory effects on IAV-induced secretion of the inflammatory cytokine, and IAV-induced infiltration of inflammatory cell into the lung tissue. Accordingly, the fusion protein is useful for developing a medicament for the treatment or prophylaxis of IAV infection and/or ameliorating pulmonary injury caused by excessive inflammation associated with IAV infection in a subject.
    • 本文公开了一种通过融合蛋白治疗甲型流感病毒(IAV)感染的方法。 根据本公开的一些实施方案,融合蛋白包含HBD肽和IgG1 Fc区。 根据本公开的其它实施方案,融合蛋白包含DcR3蛋白和IgG1 Fc区。 发现本发现的融合蛋白具有对IAV诱导的炎症细胞因子分泌的抑制作用,并且IAV诱导的炎性细胞浸润到肺组织中。 因此,融合蛋白可用于开发用于治疗或预防IAV感染和/或改善由受试者中与IAV感染相关的过度炎症引起的肺损伤的药物。
    • 27. 发明申请
    • ANTIBODIES AND METHOD FOR DETERMINING DELETIONS IN HBV PRE-S2 REGION
    • 用于确定HBV PRE-S2区域中的删除的抗体和方法
    • WO2016093823A1
    • 2016-06-16
    • PCT/US2014/069551
    • 2014-12-10
    • NATIONAL HEALTH RESEARCH INSTITUTESWANG, Lu-Hai
    • HUANG, WenyaSU, Ih-JenLEE, Yun-Ping
    • A61K39/29
    • C07K16/082G01N33/543G01N33/56983G01N2333/02
    • A HBS-specific antibody, a LHBS-specific antibody, a WT LHBS-specific antibody, an immunoassay kit comprising the antibodies, and a method of detecting pre-S2 deletion mutant LHBS using the immunoassay kit are disclosed herein. The method comprises incubating a biological sample with a first antibody to captured HBS proteins; detecting the LHBS and WT LHBS bound to the immobilized first antibody, respectively; and calculating the amount of the pre-S2 deletion mutant LHBS protein by subtracting the amount of the WT LHBS protein from that of the LHBS protein. Advantageously, by the method described herein, the amount of the pre-S2 deletion mutant LHBS, a potential high-risk marker for HCC incidence in chronic HBV carriers and recurrence in HCC patients after hepatectomy surgery, in a biological sample may be easily calculated without mutual influence between the WT and pre-S mutant LHBS while reducing the labor-intensive process for cloning each gene product before analysis.
    • 本文公开了HBS特异性抗体,LHBS特异性抗体,WT LHBS特异性抗体,包含抗体的免疫测定试剂盒和使用免疫测定试剂盒检测pre-S2缺失突变体LHBS的方法。 该方法包括将生物样品与捕获的HBS蛋白质的第一抗体孵育; 分别检测与固定的第一抗体结合的LHBS和WT LHBS; 并通过从LHBS蛋白的那些减去WT LHBS蛋白质的量来计算前S2缺失突变体LHBS蛋白质的量。 有利地,通过本文所述的方法,可以容易地计算生物样品中pre-S2缺失突变体LHBS的量,即慢性HBV携带者中HCC发生率的潜在高危标志物和肝切除手术后肝细胞癌患者的复发,而没有 WT和前S突变体LHBS之间的相互影响,同时减少分析前克隆每种基因产物的劳动密集型过程。
    • 30. 发明申请
    • IMPROVEMENTS IN PASTEURIZED EGGS
    • 化妆品中的改良剂
    • WO2003013278A1
    • 2003-02-20
    • PCT/US2002/005771
    • 2002-02-28
    • DAVIDSON, L. JohnWAGNER, Myron A.
    • DAVIDSON, L. JohnWAGNER, Myron A.
    • A23L1/32
    • A23B5/12A23B5/0052A23B5/10A23B5/14A23B5/18A23L15/00A23L15/30
    • There is provided a process for pasteurizing in shell chicken eggs (2) carried in stacks (1) by placing the eggs in a heated fluid bath (4) having a temperature of between about 128 to 145 degrees F., allowing the eggs to dwell in the heated fluid bath until there is a log reduction of at least 4.6 of any Salmonella bacteria within the eggs, removing the eggs from the heated liquid bath and into a gaseous atmosphere (26), and contacting the eggs with an antibacterial fluid (28) containing an antibacterial agent. Preferably, the eggs are thereafter contacted with a sealant such as wax. In the gaseous atmosphere the eggs further pasteurize to at least a 5 logs reduction of the bacteria by way of residual heat in the eggs. During cooling in the gaseous atmosphere, the eggs suck the antibacterial fluid into the eggs between the inside of the shells and the membranes and provide antibacterial barriers in the eggs.
    • 提供了一种通过将蛋放置在温度在约128至145华氏度的加热流体浴(4)中的层叠(1)中携带的壳鸡蛋(2)中进行巴氏消毒的方法,允许蛋停留 在加热的液体浴中,直到鸡蛋内任何沙门氏菌细菌至少有4.6的对数减少,将鸡蛋从加热的液体浴中移出并进入气态气氛(26),并使蛋与抗菌液接触(28 )含有抗菌剂。 优选地,蛋之后与诸如蜡的密封剂接触。 在气态气氛中,蛋通过鸡蛋中的残余热量进一步巴氏杀菌至少5天的细菌减少。 在气体气氛冷却期间,鸡蛋将抗菌流体吸收到壳内部和蛋壳之间的蛋中,并在鸡蛋中提供抗菌屏障。